Gynecologic Oncology Consult

Vaginal intraepithelial neoplasia: What to do when dysplasia persists after hysterectomy


 

Radiation

Intracavitary brachytherapy is a technique in which a radiation source is placed within a cylinder or ovoids and placed within the vagina.7 Typically 45 Gy is delivered to a depth 0.5mm below the vaginal mucosal surface (“point z”). Recurrence occurs is approximately 10%-15% of patients, and toxicities can be severe, including vaginal stenosis and ulceration. This aggressive therapy typically is best reserved for cases that are refractory to other therapies. Following radiation, subsequent treatments are more difficult because of radiation-induced changes to the vaginal mucosa that can affect healing.

Vaginal dysplasia is a relatively common sequelae of high-risk HPV, particularly among women who have had a prior hysterectomy for cervical dysplasia. Because of anatomic changes following hysterectomy, adequate visualization and comprehensive vaginal treatment is difficult. Therefore, surgeons should avoid utilization of hysterectomy as a routine strategy to “cure” dysplasia as it may fail to achieve this cure and make subsequent evaluations and treatments of persistent dysplasia more difficult. Women who have had a hysterectomy for dysplasia should be closely followed for several decades, and they should be counseled that they have a persistent risk for vaginal disease. When VAIN develops, clinicians should consider topical therapies as primary treatment options because they may minimize toxicity and have high rates of enduring response.

Dr. Rossi is an assistant professor in the division of gynecologic oncology at the University of North Carolina at Chapel Hill. She had no relevant conflicts of interest.

References

1. Gynecol Oncol. 2016 Jun;141(3):507-10.

2. Arch Gynecol Obstet. 2016 Feb;293(2):415-9.

3. Anticancer Res. 2013 Jan;33(1):29-38.

4. Obstet Gynecol. 2017 Dec;130(6):1237-43.

5. Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:129-36.

6. J Low Genit Tract Dis. 2014 Apr;18(2):115-21.

7. Gynecol Oncol. 2007 Jul;106(1):105-11.

Pages

Recommended Reading

IVF linked to slight increase in risk of some cancers
MDedge ObGyn
Immunogenicity of two-dose Gardasil 9 persists at 36 months
MDedge ObGyn
ACA coverage mandate leads to more insurance for young women, early gynecologic cancer diagnoses
MDedge ObGyn
PARP inhibitors didn’t impair QOL as ovarian cancer maintenance therapy
MDedge ObGyn
When is hysterectomy appropriate for cervical dysplasia?
MDedge ObGyn
Phase 2 trial: Dendritic cell vaccine maintenance prolongs PFS in EOC
MDedge ObGyn
VEGF inhibitor shows promise in platinum resistant/refractory ovarian cancer
MDedge ObGyn
First-ever gestational trophoblastic neoplasia guidelines published
MDedge ObGyn
Cervical cancer screening recommendations vary by age and risk
MDedge ObGyn
Pruritus linked to wide variety of cancers
MDedge ObGyn